Free Trial Information
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...development officer. Zung joins from WCG Clinical, where he was president of sponsor and CRO programs. Equillium Inc....
Read More
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...EUA. “We’ll hopefully build up thousands of patients-worth of data,” she said. In the U.S., Equillium Inc....
Read More
BioCentury | Jul 14, 2020
Product Development

Immune-targeted mAb from Biocon, Equillium to enter global trials after Indian approval in COVID-19 patients

...approval in India has prompted Equillium to send the immune modulator into a global testing. Equillium Inc....
...the adaptive study (see “UK Approves Steroid” ). Sandi Wong, Assistant Editor Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6 cov19count COVID-19 chs20 cov19count...
Read More
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...NASDAQ:OSMT) 10/17/18 $53.5 $367.6 $407.0 11% PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) 10/17/18 $49.3 $122.5 $75.7 -38% Equillium Inc....
Read More
BioCentury | Oct 19, 2018
Financial News

Equillium prices $65.4M IPO

...Autoimmune and inflammatory disease company Equillium Inc. (NASDAQ:EQ) raised $65.4 million in an IPO on Oct. 12...
...Proposes $86.3M IPO” ). Equillium Inc. (NASDAQ:EQ), La Jolla Calif. Jaime De Leon Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6...
Read More
BioCentury | Sep 21, 2018
Financial News

Equillium proposes $86.3M IPO

...Autoimmune and inflammatory disease company Equillium Inc. (La Jolla, Calif.) proposed to raise up to $86.3 million...
...issuance of convertible promissory notes. Equillium Inc., La Jolla, Calif. Jaime De Leon Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6...
Read More
Items per page:
1 - 6 of 6
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...development officer. Zung joins from WCG Clinical, where he was president of sponsor and CRO programs. Equillium Inc....
Read More
BioCentury | Aug 1, 2020
Product Development

Will Biocon’s COVID-19 anti-inflammatory succeed where IL-6 blockers have failed?

...EUA. “We’ll hopefully build up thousands of patients-worth of data,” she said. In the U.S., Equillium Inc....
Read More
BioCentury | Jul 14, 2020
Product Development

Immune-targeted mAb from Biocon, Equillium to enter global trials after Indian approval in COVID-19 patients

...approval in India has prompted Equillium to send the immune modulator into a global testing. Equillium Inc....
...the adaptive study (see “UK Approves Steroid” ). Sandi Wong, Assistant Editor Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6 cov19count COVID-19 chs20 cov19count...
Read More
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...NASDAQ:OSMT) 10/17/18 $53.5 $367.6 $407.0 11% PhaseBio Pharmaceuticals Inc. (NASDAQ:PHAS) 10/17/18 $49.3 $122.5 $75.7 -38% Equillium Inc....
Read More
BioCentury | Oct 19, 2018
Financial News

Equillium prices $65.4M IPO

...Autoimmune and inflammatory disease company Equillium Inc. (NASDAQ:EQ) raised $65.4 million in an IPO on Oct. 12...
...Proposes $86.3M IPO” ). Equillium Inc. (NASDAQ:EQ), La Jolla Calif. Jaime De Leon Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6...
Read More
BioCentury | Sep 21, 2018
Financial News

Equillium proposes $86.3M IPO

...Autoimmune and inflammatory disease company Equillium Inc. (La Jolla, Calif.) proposed to raise up to $86.3 million...
...issuance of convertible promissory notes. Equillium Inc., La Jolla, Calif. Jaime De Leon Alzumab, itolizumab (EQ001, anti-cd6, t1h) Biocon Ltd. Equillium Inc. CD6...
Read More
Items per page:
1 - 6 of 6